All case companies identify this strategy as their primary effort for managing the increasing lead times.
A comparison of clinical studies that were identified using this strategy with studies obtained using a broader search strategy did not identify additional relevant studies.
Three compounds were identified through this strategy to inhibit LTA4H-h and hnps-PLA2 simultaneously [35].
The start times of corresponding speech and gesture pairs should not differ greatly, and the correspondences were better identified using this strategy than by the 'nearest matching' and 'longest overlapping time' strategies described in Section 5.1.
Five in vivo-induced (ivi) operons have been identified using this strategy, originally based on the use of an auxotrophic marker.
Genes coding for recognition, signaling, and defense components have been identified with this strategy as candidates to explain resistance QTLs in several plant species [13], [14], [21], [22], [43], [44].
However, no additional QTL was identified using this strategy.
MMP7 is one of the markers identified by this strategy.
Consequently, most genes identified by this strategy were only partly spanned by FcB1-schizont-ESTs FcB1-schizont-ESTs FcB1-schizont-ESTs
One novel compound identified by this strategy is tubacin, a specific inhibitor of HDAC6 [ 21].
